Expert Opinion on Pharmacotherapy最新文献_第4页

Tackling multidrug-resistant Gram-negative infections in children globally: current therapeutic options and perspectives. 应对全球儿童多重耐药革兰氏阴性感染：目前的治疗选择和前景。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-23 DOI: 10.1080/14656566.2025.2519690

Lorenzo Chiusaroli, Costanza Tripiciano, Cecilia Liberati, Marica De Pieri, Giulia Brigadoi, Daniele Donà

{"title":"Tackling multidrug-resistant Gram-negative infections in children globally: current therapeutic options and perspectives.","authors":"Lorenzo Chiusaroli, Costanza Tripiciano, Cecilia Liberati, Marica De Pieri, Giulia Brigadoi, Daniele Donà","doi":"10.1080/14656566.2025.2519690","DOIUrl":"10.1080/14656566.2025.2519690","url":null,"abstract":"Introduction: Over the past two decades, the global burden of multidrug-resistant organisms has grown steadily, representing a major concern in pediatric healthcare. Among these, hospital-acquired infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) are particularly challenging to manage in children, due to limited therapeutic options and the scarcity of pharmacokinetic data in the pediatric population. Although several new antibiotics - especially β-lactams combined with β-lactamase inhibitors - have become available, uncertainties remain regarding their optimal use in pediatric populations.Areas covered: This review explores potential treatment strategies for MDR-GNB infections in children, with a focus on pathogens listed in the WHO priority list. It examines the pharmacological properties of both traditional and newly approved antibiotics, assessing their role and applicability in pediatric clinical practice.Expert opinion: New β-lactam antibiotics, alone or in combination with β-lactamase inhibitors - such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol - have emerged as preferred options for treating carbapenem-resistant and difficult-to-treat Gram-negative infections. Therapy should be guided by pathogen identification and resistance mechanisms, as susceptibility profiles vary widely based on the resistance-mechanism. Older agents like colistin, fosfomycin, nitrofurantoin, and aminoglycosides remain important, particularly in resource-limited settings, despite concerns over toxicity and safety.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1205-1220"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors. 低级别IDH突变胶质瘤：从标准的术后治疗到新型IDH抑制剂。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1080/14656566.2025.2516617

Roberta Rudà, Francesco Bruno, Alessia Pellerino, Edoardo Pronello, Riccardo Soffietti

{"title":"Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors.","authors":"Roberta Rudà, Francesco Bruno, Alessia Pellerino, Edoardo Pronello, Riccardo Soffietti","doi":"10.1080/14656566.2025.2516617","DOIUrl":"10.1080/14656566.2025.2516617","url":null,"abstract":"Introduction: Adult-type IDH-mutant diffuse gliomas grade 2 are rare tumors mainly affecting young patients, classified by WHO 2021 into IDH-mutant astrocytomas and IDH-mutant 1p/19q codeleted oligodendrogliomas. IDH-mutant grade 2 gliomas are slowly growing tumors; however, they grow continuously, and almost all patients will ultimately recur. Surgical resection is the first option, followed by observation with MRI in low-risk patients and radio-chemotherapy in high-risk patients. Early clinical trials and phase 3 INDIGO trial have demonstrated the efficacy of vorasidenib, a dual IDH1/2 inhibitor, in prolonging imaging-based progression-free survival and time-to-next-intervention.Areas covered: This review covers the following areas: importance of surgical resection, traditional treatments after surgery, mechanisms of IDH mutations and IDH inhibitors in preclinical models, early clinical studies on ivosidenib and vorasidenib, INDIGO trial, the future role of vorasidenib, open issues beyond INDIGO trial, and novel IDH targeting strategies.Expert opinion: IDH1/2 mutations are ideal targets of therapy and early clinical studies and INDIGO phase 3 trial confirmed the clinical efficacy of vorasidenib. Long-term follow-up is needed to better define the efficacy across different subgroups of patients. Overall, vorasidenib will replace observation with MRI for low-risk patients and allow to delay radiotherapy and chemotherapy and their adverse effects.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1163-1175"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. 用真实世界数据评估西马鲁肽对2型糖尿病患者慢性肾脏疾病风险的影响的外部对照。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-13 DOI: 10.1080/14656566.2025.2518329

Onur Baser, Yuanqing Lu

{"title":"External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes.","authors":"Onur Baser, Yuanqing Lu","doi":"10.1080/14656566.2025.2518329","DOIUrl":"10.1080/14656566.2025.2518329","url":null,"abstract":"Background: Clinical trials have shown semaglutide effective in mitigating risks associated with type 2 diabetes and chronic kidney disease. However, semaglutide's real-world effectiveness and long-term outcomes are not fully established.Research design & methods: Using 2019-2024 Kythera Labs data, an external control arm was created using criteria identified in the FLOW clinical trial. Primary outcomes were major kidney disease events (kidney failure onset and ≥ 50% reduction in estimated glomerular filtration rate from baseline). Propensity score matching and Cox regression were used to determine risk-adjusted outcomes.Results: The control arm (n = 896,257) was compared with the clinical trial cohort (n = 1,766). After propensity score matching on age, sex, socioeconomic status, and comorbidities, semaglutide treatment was associated with a 26% reduction in primary event risk compared with the comparator group (702 vs 1,068 events; HR: 0.74; 95% CI, 0.67-0.81), consistent with the 24% risk reduction observed in the clinical trial.Conclusion: Semaglutide treatment was linked to a significantly lower risk of clinically relevant renal outcomes. Our findings provide robust real-world evidence that supports the FLOW trial results regarding the renoprotective effects of semaglutide, highlighting its promise as an effective therapeutic option for managing renal complications.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1237-1243"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hereditary angioedema treatment beyond biologics: current state of preventive and on-demand approaches and new perspectives. 超越生物制剂的遗传性血管性水肿治疗：预防和按需方法的现状和新观点。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-24 DOI: 10.1080/14656566.2025.2509782

Andrea Zanichelli, Giada De Angeli, Irene Baroni, Marta Mansi, Giuseppe Caravella, Rosario Caruso

{"title":"Hereditary angioedema treatment beyond biologics: current state of preventive and on-demand approaches and new perspectives.","authors":"Andrea Zanichelli, Giada De Angeli, Irene Baroni, Marta Mansi, Giuseppe Caravella, Rosario Caruso","doi":"10.1080/14656566.2025.2509782","DOIUrl":"10.1080/14656566.2025.2509782","url":null,"abstract":"Introduction: Hereditary angioedema (HAE) is a genetic rare condition characterized by recurrent attacks of swelling that might be potentially life-threatening. Recurrence and severity of attacks may impact psychological life, expectations and productivity. We aim to review the state-of-the-art of HAE preventive and on-demand treatment of non-biologic drugs, providing a perspective of their personalized use and development.Areas covered: This literature analysis integrates international guidelines and clinical trial data on on-demand therapies and short-/long-term prophylaxis. Modern medications should be considered and personalized for HAE patients to provide benefits compatible with patients' lifestyles, preferences, and experiences. Accordingly, a new era toward oral formulations has begun starting from berotralstat, with a consistent number of drugs under development.Expert opinion: All HAE patients should have an effective on-demand treatment available in case of attacks. Long-term prophylaxis (LTP) should be considered and individualized for all patients at every visit, following a shared decision-making approach to optimize disease control while limiting side effects. Parenteral administration of LTP is associated with treatment complexities and barriers. Oral treatment could address practical needs for HAE patients both in preventive and on-demand setting, avoiding injection-related side effects, reducing treatment burden, and improving quality of life. In the next future, significant advances in HAE therapeutics could result from gene therapy.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1221-1228"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and emerging pharmacotherapies in Lennox-Gastaut syndrome. lenox - gastaut综合征的当前和新兴药物治疗。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-29 DOI: 10.1080/14656566.2025.2516630

Debopam Samanta, Manan Nath

{"title":"Current and emerging pharmacotherapies in Lennox-Gastaut syndrome.","authors":"Debopam Samanta, Manan Nath","doi":"10.1080/14656566.2025.2516630","DOIUrl":"10.1080/14656566.2025.2516630","url":null,"abstract":"Introduction: Lennox-Gastaut syndrome (LGS) is a severe childhood-onset developmental and epileptic encephalopathy characterized by multiple drug-resistant seizures, cognitive impairments, and distinctive EEG patterns. Given its profound impact on patients' quality of life, developing effective pharmacotherapies remains a critical clinical challenge.Areas covered: This review examines FDA-approved medications for LGS (clonazepam, felbamate, lamotrigine, topiramate, rufinamide, clobazam, cannabidiol, and fenfluramine), commonly used off-label antiseizure medications, emerging treatments in clinical trials, and precision therapeutics targeting etiology-specific mechanisms. The literature encompasses randomized controlled trials, observational studies, and expert consensus statements on treatment approaches and challenges.Expert opinion: Despite therapeutic advances, most patients with LGS lack individualized treatment plans with regular adjustments. Current management requires a multimodal approach integrating pharmacotherapy with other interventions. Future progress depends on improved natural history studies, standardized data collection, advanced preclinical models, innovative trial designs, and addressing healthcare inequities. While emerging precision therapies targeting genetic causes show promise, the field urgently needs better strategies to optimize existing treatments while developing disease-modifying approaches that address both seizures and non-seizure outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1133-1147"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting treatment response to GLP-1 receptor agonists: still tossing the coin or doing better? 预测GLP-1受体激动剂的治疗反应：还在掷硬币还是做得更好？

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-08 DOI: 10.1080/14656566.2025.2517802

Maria Apostolopoulou, Theocharis Koufakis

引用次数: 0

Advancing care in primary biliary cholangitis: emerging insights and novel therapies. 推进原发性胆管炎的护理：新见解和新疗法。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-16 DOI: 10.1080/14656566.2025.2516622

Marius Vögelin, Andreas E Kremer

{"title":"Advancing care in primary biliary cholangitis: emerging insights and novel therapies.","authors":"Marius Vögelin, Andreas E Kremer","doi":"10.1080/14656566.2025.2516622","DOIUrl":"10.1080/14656566.2025.2516622","url":null,"abstract":"Introduction: Primary biliary cholangitis (PBC) is a chronic, cholestatic liver disease, is associated with fatigue and pruritus and can progress to cirrhosis if left untreated. Ursodeoxycholic acid (UDCA) has been the mainstay of therapy for over 40 years. However, 30-40% of PBC patients do not adequately respond to UDCA or have risk factors for disease progression and require second-line treatment.Areas covered: Recent international cohort analyses have provided new insights that enable early identification of high-risk PBC patients and suggest that stricter treatment goals may lower mortality and reduce the need for liver transplantation. Alongside established second-line agents, several promising substances have progressed to phase 2 and 3 trials. Notably, seladelpar and elafibranor, two selective agonists of peroxisome proliferator-activated receptors, achieved high rates of biochemical response and good tolerability, leading to their recent approval for second-line treatment of PBC. Moreover, dedicated clinical trials addressed fatigue and pruritus, the two main symptoms of PBC.Expert opinion: Personalized treatment approaches for PBC are both feasible and essential to improve biochemical response, extend transplant-free survival and alleviate symptom burden. Well-tolerated novel therapies are poised to reshape the treatment landscape in the near future.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1149-1162"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eosinophilic esophagitis in children: new kids on the block. 儿童嗜酸性粒细胞性食管炎：新来的孩子。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-16 DOI: 10.1080/14656566.2025.2517801

Cosimo Ruggiero, Giovanna Alfano, Lucy Jackman, Giusy Russo, Danila Volpe, Edward Gaynor, Leanne Goh, Salvatore Oliva, Osvaldo Borrelli

{"title":"Eosinophilic esophagitis in children: new kids on the block.","authors":"Cosimo Ruggiero, Giovanna Alfano, Lucy Jackman, Giusy Russo, Danila Volpe, Edward Gaynor, Leanne Goh, Salvatore Oliva, Osvaldo Borrelli","doi":"10.1080/14656566.2025.2517801","DOIUrl":"10.1080/14656566.2025.2517801","url":null,"abstract":"Introduction: Eosinophilic esophagitis (EoE) is an immune-mediated disease characterized by esophageal dysfunction and eosinophil rich inflammatory infiltrate. Its incidence is rising globally due to increased awareness, improved diagnostics, and environmental and genetic factors. EoE is driven by a Th2-mediated immune response to food and environmental allergens, leading to chronic inflammation, epithelial barrier dysfunction and progressive esophageal remodeling.Areas covered: This review explores pediatric EoE, focusing on epidemiology, pathogenesis, clinical presentation, diagnosis, and both standard and new treatment strategies. Symptoms vary by age, from feeding difficulties in infants to dysphagia and food impaction in older children. Diagnosis relies on clinical symptoms, endoscopic findings and histologic assessment. Standard treatments include dietary elimination, proton pump inhibitors and topical corticosteroids, while biologic therapies such as dupilumab offer targeted alternatives for refractory cases.Expert opinion: Future research focuses on optimizing treatment sequencing (step-up and step-down approach), exploring non-eosinophil-mediated inflammation, and enhancing noninvasive test to predict disease severity and phenotypes for better long-term management.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1117-1132"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effectiveness and safety of administering antiplatelet medications following reperfusion therapy in patients with ischemic stroke. 缺血性卒中患者再灌注治疗后给予抗血小板药物的有效性和安全性。

IF 2.7 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-19 DOI: 10.1080/14656566.2025.2521371

Xiaoning Ju, Ningfen Wang, Yubin Wu, Guoqing Wang

{"title":"The effectiveness and safety of administering antiplatelet medications following reperfusion therapy in patients with ischemic stroke.","authors":"Xiaoning Ju, Ningfen Wang, Yubin Wu, Guoqing Wang","doi":"10.1080/14656566.2025.2521371","DOIUrl":"10.1080/14656566.2025.2521371","url":null,"abstract":"Background: Ischemic stroke is a major cause of morbidity and mortality worldwide. Although reperfusion therapy enhances patient outcomes, the ideal antiplatelet regimen post-treatment remains unclear. This study investigates the efficacy and safety of dual antiplatelet therapy (DAPT) versus triple antiplatelet therapy (TAT) in ischemic stroke patients after reperfusion.Research design and methods: A retrospective observational analysis was conducted on 730 patients treated at a single institution from January 2018 to December 2023. Patients were divided into two groups: DAPT (aspirin and clopidogrel) or TAT (aspirin, clopidogrel, and tirofiban). Outcomes included neurological improvement via NIHSS scores, functional recovery using mRS, and bleeding complications.Results: TAT demonstrated significantly better neurological recovery, with more patients achieving NIHSS ≤ 3 (p < 0.001). All TAT patients had mRS ≤ 2 at 30 days. However, TAT was associated with higher bleeding rates (37.4% vs. 18.8%, p < 0.05). Intravenous thrombolysis increased bleeding risk (OR = 3.95, 95% CI: 1.26-12.44, p = 0.02).Conclusion: TAT may enhance neurological recovery but increases bleeding risk. Patient selection and monitoring are crucial, and long-term studies are needed to fully evaluate its risk-benefit profile.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1245-1254"},"PeriodicalIF":2.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New strategies for the management of biofilms formed by Gram-negative bacteria. 革兰氏阴性菌形成的生物膜管理的新策略。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-17 DOI: 10.1080/14656566.2025.2519692

Cristina Ortega-Portas, Jaime Esteban

{"title":"New strategies for the management of biofilms formed by Gram-negative bacteria.","authors":"Cristina Ortega-Portas, Jaime Esteban","doi":"10.1080/14656566.2025.2519692","DOIUrl":"10.1080/14656566.2025.2519692","url":null,"abstract":"Introduction: The global rise of multidrug-resistant (MDR) Gram-negative bacteria (GNB) has intensified the threat of chronic and hard-to-treat infections, many of which are associated with biofilm formation. These biofilms confer enhanced resistance to antimicrobials and immune responses, posing a major clinical challenge.Areas covered: This review summarizes the biological mechanisms of biofilm formation in GNB and explores both traditional and novel strategies for their prevention and eradication. The literature search covered peer-reviewed articles from major databases, focusing on therapeutic approaches such as quorum sensing inhibitors, EPS matrix disruptors, phage therapy, nanotechnology, and synergistic drug combinations. The novelty of this review lies in its effort to understand biofilm biology to identify key intervention points and organize therapeutic strategies according to their biological, chemical or physical nature. Emphasis is also placed on combined approaches that simultaneously target multiple components of the biofilm structure.Expert opinion: Despite significant in vitro progress, most antibiofilm strategies remain experimental. Translating these findings into clinical applications requires standardization, in vivo validation, and regulatory alignment. A multidisciplinary approach integrating different agents and targeted drug delivery systems holds promise for improving patient outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1191-1203"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0